Synedgen

Synedgen is a Honolulu-based biotechnology company specializing in the development of first-in-class therapeutics that promote barrier function and repair mucosal injury in gastrointestinal (GI) diseases. Their lead asset, MIIST305, is an orally delivered therapeutic that restores GI function, reduces inflammation, and protects against damage.

With a strong IP position and scalable GMP production, Synedgen's targeted therapies have demonstrated excellent safety profiles and efficacy across multiple modalities, making them a promising player in the field of regenerative therapeutics.

Generated from the website